iv ketamine
Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)
ketamine
Spotlight: Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025)
"In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4–5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."
ketamine
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)
"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
ketamine
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)
Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión
antidepressants
Spotlight: Large responses to antidepressants or methodological artifacts? A secondary analysis of STAR∗D, a single-arm, open-label, nonindustry antidepressant trial (Xu, et al, 2025)
"...our results do not support the notion that a subgroup of patients with a large response exists. Instead, these findings support the assumption that the putative subgroups from industry randomized controlled trials may be artifacts caused by methodological biases."
psilocybin
Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)
"when it comes to reducing depression with psychedelic-assisted therapy, what matters even more than the drug is a strong relationship between the therapist and study participant."
ketamine
Spotlight: "Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers" (Flynn, et al, 2025)
"Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder."
ketamine
Spotlight: Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis (Bhatt, et al, 2025)
Experiencia mística de la ketamina en veteranos con depresión resistente en tratamiento: un análisis exploratorio retrospectivo
ketamine
Spotlight: The Effectiveness of Combining Ketamine and Cognitive Behavioural Therapy in Treating Major Depressive Disorder (2025)
" This study seeks to investigate the combined effectiveness of ketamine and CBT in the treatment of MDD, with the hypothesis that integrated treatment will outperform either modality administered alone."
ketamine
Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)
"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."
mdma
Spotlight: MDMA + Psychotherapy as a treatment for major depressive disorder: proof of principle study (Kvam, et al, 2025)
"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."
ketamine repeated doses
Spotlight: Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."
fda
Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression
"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
cancer
Spotlight: Long-term benefits of single-dose psilocybin in depressed patients with cancer (Agrawal, et al, 2025)
"These findings demonstrate robust antidepressive activity from a single 25 mg dose of psilocybin combined with psychotherapy and suggest a potentially paradigm-changing alternative to traditional antidepressants requiring further study."
cannabis
Spotlight: UK Medical Cannabis Registry: A clinical outcomes analysis for insomnia (Aggarwal, et al, 2025)
"The study demonstrated improvements in subjective sleep quality and other captured PROMs in insomnia patients treated with cannabis-based medicinal products."
ketamine
Spotlight: New and emerging pharmacologic treatments for MDD (Uyar, et al, 2025)
"Clinical trials have demonstrated the ability of ketamine to quickly reduce symptoms, particularly in treatment-resistant cases, with effects noticeable within hours and lasting several days post-administration."
ketamine
Spotlight: Ketamine Reverses Chronic Stress-Induced Behavioral Changes via the Expression of Ca2+-Permeable AMPA Receptors in Mice (Flowers, et al, 2025)
"Our findings suggest that subanesthetic low-dose ketamine rapidly triggers the expression of CP-AMPARs in the hippocampus, which induces antidepressant and antistress effects."
ketamine
Spotlight: Intravenous ketamine for suicide ideation in borderline personality and depression (Bachir, et al, 2025)
"This report highlights ketamine's rapid action on glutamate pathways and its potential benefits in complex psychiatric profiles where traditional treatments like electroconvulsive therapy often fail. "